TY - JOUR
T1 - Molecular and cellular biomarkers for angiogenesis in clinical oncology
AU - Bertolini, Francesco
AU - Mancuso, Patrizia
AU - Shaked, Yuval
AU - Kerbel, Robert S.
PY - 2007/10
Y1 - 2007/10
N2 - Medical oncologists are increasingly using anti-angiogenic drugs, but identifying the best-suited drug and the optimal dosage and schedule for treatment of patients remain challenging issues. Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) are modulated in a variety of diseases including cancer, and are promising surrogate biomarkers in oncology. Molecular surrogate markers, on the other hand, are more scanty at the present time, because the identification of truly endothelial cell-restricted genes and/or antigens is complex. Here, we discuss the biological and technical facets of the search and validation of new biomarkers for angiogenesis.
AB - Medical oncologists are increasingly using anti-angiogenic drugs, but identifying the best-suited drug and the optimal dosage and schedule for treatment of patients remain challenging issues. Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) are modulated in a variety of diseases including cancer, and are promising surrogate biomarkers in oncology. Molecular surrogate markers, on the other hand, are more scanty at the present time, because the identification of truly endothelial cell-restricted genes and/or antigens is complex. Here, we discuss the biological and technical facets of the search and validation of new biomarkers for angiogenesis.
UR - http://www.scopus.com/inward/record.url?scp=35148820611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35148820611&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2007.08.011
DO - 10.1016/j.drudis.2007.08.011
M3 - Article
C2 - 17933680
AN - SCOPUS:35148820611
VL - 12
SP - 806
EP - 812
JO - Drug Discovery Today
JF - Drug Discovery Today
SN - 1359-6446
IS - 19-20
ER -